Netanya, Israel-based medical device company Sorrel Medical develops and manufactures pre-filled wearable injectors for the easy and efficient self-administration of large volume and high viscosity medications.
One of three privately held companies operating under the Eitan Group, Sorrel leverages core capabilities and expertise in drug delivery technology development, manufacturing and regulatory experience to offer a robust platform solution to the healthcare market. With innovative technology solutions, Sorrel’s devices address the need for partner-oriented and patient-centric drug delivery systems.
“Sorrel is committed to providing simple and easy to use solutions that enhance the self-administration experience while encouraging adherence to treatment therapies. Creating a truly patient-centric experience, our devices are discreet, fully-disposable, and able to meet a variety of specific drug requirements from multiple pharmaceutical partners,” said Andrei Yosef, Ph.D., CEO for Sorrel Medical.
Sorrel recently won “Best New Technology Solution in Drug Delivery” designation from MedTech Breakthrough, an independent organization, said a press release.
Sorrel’s wearable devices are designed to accommodate drug reservoirs ranging from 1 mL to 20 mL in volume. The devices utilize a variety of smart sensors to guarantee successful self-administration and first-of-its-kind UV LED technology to provide disinfection at point-of-care – addressing a longstanding challenge in pre-filled drug delivery devices. Finally, the devices are able to connect to both Bluetooth and near-field communication (NFC) platforms, allowing patients to share treatment information with caregivers, healthcare providers, and other necessary stakeholders.